Bio-Techne Corp. (TECH)

209.47
NASDAQ : Health Technology
Prev Close 214.42
Day Low/High 209.13 / 216.09
52 Wk Low/High 132.75 / 217.16
Avg Volume 142.30K
Exchange NASDAQ
Shares Outstanding 37.87M
Market Cap 8.12B
EPS 3.40
P/E Ratio 67.22
Div & Yield 1.28 (0.61%)

Latest News

Bio-Techne Announces Commercial Release Of RNAscope® HiPlex Assay: A Multiplex In Situ Hybridization Assay For Tissues

Bio-Techne Announces Commercial Release Of RNAscope® HiPlex Assay: A Multiplex In Situ Hybridization Assay For Tissues

Expanding research tools for Spatial Genomics by combining molecular information with spatial context in one simple assay.

Bio-Techne CEO Chuck Kummeth Wins Entrepreneur Of The Year® 2019 Award In The Heartland

Bio-Techne CEO Chuck Kummeth Wins Entrepreneur Of The Year® 2019 Award In The Heartland

MINNEAPOLIS, July 9, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that its President and CEO, Chuck Kummeth, was recently honored with the EY Entrepreneur Of The Year ® 2019 Award in the Heartland.

Bio-Techne China Recognized With "Decade Of Contribution Award"

Bio-Techne China Recognized With "Decade Of Contribution Award"

MINNEAPOLIS, June 26, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) was recently honored with the "Decade of Contribution Award" at the 2019 (10th) International Conference on Cell Therapy conference.

Bio-Techne Appoints Rupert Vessey To Board Of Directors

Bio-Techne Appoints Rupert Vessey To Board Of Directors

MINNEAPOLIS, June 25, 2019 /PRNewswire/ -- Bio-Techne Corporation today announced the appointment of Dr.

FDA Grants Breakthrough Device Designation To Bio-Techne's ExoDx™ Prostate IntelliScore™ (EPI) Test

FDA Grants Breakthrough Device Designation To Bio-Techne's ExoDx™ Prostate IntelliScore™ (EPI) Test

MINNEAPOLIS, June 17, 2019 /PRNewswire/ -- Bio-Techne today announced that the U.

Bio-Techne Receives Approval To Offer The ExoDx™ Prostate Intelliscore™ (EPI) Test In New York State

Bio-Techne Receives Approval To Offer The ExoDx™ Prostate Intelliscore™ (EPI) Test In New York State

The EPI prostate biopsy rule-out test is now available in every state

Bio-Techne To Acquire B-MoGen Biotechnologies Inc.

Bio-Techne To Acquire B-MoGen Biotechnologies Inc.

MINNEAPOLIS, June 4, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced today it has reached agreement to acquire all of the stock of B-MoGen Biotechnologies Inc.

Bio-Techne To Present At The Goldman Sachs 40th Annual Global Healthcare Conference

Bio-Techne To Present At The Goldman Sachs 40th Annual Global Healthcare Conference

MINNEAPOLIS, June 3, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Goldman Sachs 40 th Annual Global Healthcare Conference on Tuesday, June 11 th,...

Bio-Techne's New Exosome-Based Liquid Biopsies Helping To Advance Personalized Care In Lung Cancer Diagnostics

Bio-Techne's New Exosome-Based Liquid Biopsies Helping To Advance Personalized Care In Lung Cancer Diagnostics

MINNEAPOLIS, May 28, 2019 /PRNewswire/ -- Bio-Techne today announced the publication of a recent validation study demonstrating that the proprietary exosome-based liquid biopsy tests from Bio-Techne's Exosome Diagnostics brand may be used to assess the...

Bio-Techne To Present At The Jefferies 2019 Global Healthcare Conference

Bio-Techne To Present At The Jefferies 2019 Global Healthcare Conference

MINNEAPOLIS, May 21, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Jefferies 2019 Global Healthcare Conference on Wednesday, June 5 th, 2019, at...

Bio-Techne To Present At The UBS Global Healthcare Conference

Bio-Techne To Present At The UBS Global Healthcare Conference

MINNEAPOLIS, May 14, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the UBS Global Healthcare Conference on Wednesday, May 22 nd, 2019, at 9:00 a.

Roche Expands Partnership With Bio-Techne To Offer Drug Discovery Researchers New Chromogenic Detection Options For MRNA ISH Tissue Analysis

Roche Expands Partnership With Bio-Techne To Offer Drug Discovery Researchers New Chromogenic Detection Options For MRNA ISH Tissue Analysis

New Roche detection kits, combined with Bio-Techne's ACD RNAscope® reagent kits, increase singleplex and multiplex testing capabilities on automated platform

Bio-Techne To Present At The Bank Of America Merrill Lynch 2019 Health Care Conference

Bio-Techne To Present At The Bank Of America Merrill Lynch 2019 Health Care Conference

MINNEAPOLIS, May 2, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Jim Hippel, Chief Financial Officer will present at the Bank of America Merrill Lynch 2019 Health Care Conference on Wednesday, May 15 th, 2019, at 2:20 p.

Bio-Techne Declares Dividend

Bio-Techne Declares Dividend

MINNEAPOLIS, April 30, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.

Bio-Techne Releases Third Quarter Fiscal 2019 Results

Bio-Techne Releases Third Quarter Fiscal 2019 Results

MINNEAPOLIS, April 30, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ended March 31, 2019.

Elpiscience And Bio-Techne Announce Strategic Collaboration

Elpiscience And Bio-Techne Announce Strategic Collaboration

SHANGHAI and MINNEAPOLIS, April 22, 2019 /PRNewswire/ --  Elpiscience BioPharma and Bio-Techne Corporation announced today that the companies have entered into a strategic collaboration for the development of anti-cancer therapeutics.

Bio-Techne To Host Conference Call On April 30, 2019 To Announce Third Quarter 2019 Financial Results

Bio-Techne To Host Conference Call On April 30, 2019 To Announce Third Quarter 2019 Financial Results

MINNEAPOLIS, April 9, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call on Tuesday, April 30, 2019 at 8:00 a.

Bio-Techne And NanoString Partner To Co-Develop Integrated Workflow For RNA Spatial Profiling

Bio-Techne And NanoString Partner To Co-Develop Integrated Workflow For RNA Spatial Profiling

-- Integrated Workflow Combines NanoString's GeoMx DSP High-Plex RNA Assays and Bio-Techne's Highly Sensitive RNAscope Imaging Reagent Portfolio --

Bio-Techne Scores A Trio Of CiteAb 2019 Awards

Bio-Techne Scores A Trio Of CiteAb 2019 Awards

MINNEAPOLIS, March 5, 2019 /PRNewswire/ -- Bio-Techne, a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, was honored with three prestigious 2019 CiteAb Awards.

Bio-Techne To Present At The Barclays Global Healthcare Conference

Bio-Techne To Present At The Barclays Global Healthcare Conference

MINNEAPOLIS, March 5, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Jim Hippel, Chief Financial Officer will present at the Barclays Global Healthcare Conference on Wednesday, March 13 th, 2019, at 9:00 a.

Bio-Techne Signs Strategic Cooperation Agreement With Lisen Imprinting Diagnostics

Bio-Techne Signs Strategic Cooperation Agreement With Lisen Imprinting Diagnostics

MINNEAPOLIS, Feb. 26, 2019 /PRNewswire/ -- Bio-Techne has entered into a strategic cooperation agreement in the precision medicine field with Lisen Imprinting Diagnostics Wuxi Co.

Bio-Techne To Present At The 8th Annual SVB Leerink Global Healthcare Conference

Bio-Techne To Present At The 8th Annual SVB Leerink Global Healthcare Conference

MINNEAPOLIS, Feb. 20, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer will present at the 8 th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 27...

Bio-Techne Declares Dividend

Bio-Techne Declares Dividend

MINNEAPOLIS, Feb. 5, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.

Bio-Techne Releases Second Quarter Fiscal 2019 Results

Bio-Techne Releases Second Quarter Fiscal 2019 Results

MINNEAPOLIS, Feb. 5, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ended December 31, 2018.

ExoDx® Prostate(IntelliScore) (EPI) Recommended In National Comprehensive Cancer Network Guidelines For Prostate Cancer Early Detection

ExoDx® Prostate(IntelliScore) (EPI) Recommended In National Comprehensive Cancer Network Guidelines For Prostate Cancer Early Detection

MINNEAPOLIS, Jan. 31, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the National Comprehensive Cancer Network (NCCN) decision to include EPI as a recommended test in their Clinical Practice Guidelines in Oncology (NCCN...

Bio-Techne Introduces 48-Digoxigenin Cartridge For The Ella Platform

Bio-Techne Introduces 48-Digoxigenin Cartridge For The Ella Platform

MINNEAPOLIS, Jan. 29, 2019 /PRNewswire/ -- Bio-Techne today announced the launch of a new customizable cartridge format for their ProteinSimple-branded Ella™ immunoassay platform.

Bio-Techne Introduces CE-SDS PLUS For Maurice™ System

Bio-Techne Introduces CE-SDS PLUS For Maurice™ System

MINNEAPOLIS, Jan. 28, 2019 /PRNewswire/ -- Bio-Techne today announced the launch of the CE-SDS PLUS system for its ProteinSimple-branded Maurice ™ platform.

Bio-Techne Launches Cell And Gene Therapy Portfolio

Bio-Techne Launches Cell And Gene Therapy Portfolio

MINNEAPOLIS, Jan. 24, 2019 /PRNewswire/ -- Bio-Techne announces the launch of their cell and gene therapy portfolio.

TheStreet Quant Rating: B+ (Buy)